BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings […]
HC Wainwright reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings […]
